The effect of the oral iron chelator deferiprone on the liver damage induced by tamoxifen in female rats

Hemoglobin

Volumn 35, Issue 3, 2011, Pages 255-261

  Černá, Pavla ^a   Kotyzovai, Dana ^a   Eybl, Vladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Deferiprone (L1); Hepatotoxicity; Iron accumulation; Oxidative stress; Tamoxifen (TAM)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; DEFERIPRONE; GLUTAMATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IRON; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TAMOXIFEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IRON METABOLISM; LIPID PEROXIDATION; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; DRUG-INDUCED LIVER INJURY; ENZYME ASSAYS; FEMALE; IRON; IRON CHELATING AGENTS; LIPID PEROXIDATION; PROTECTIVE AGENTS; PYRIDONES; RATS; RATS, WISTAR; TAMOXIFEN; TREATMENT OUTCOME;

RATTUS; RATTUS NORVEGICUS;

EID: 79957523019     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.560780     Document Type: Conference Paper

References (24)

1. Osborne CK. Drug therapy: tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22): 1609-1618 (Pubitemid 28536137)
2. Powles TJ. Efficacy of tamoxifen as treatment of breast cancer. Semin Oncol. 1997;24(1, Suppl. 1): S1-48-S1-54 (Pubitemid 27104889)
3. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1989;37(4): 451-490
4. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol. 1995;35: 195-211
5. Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol. 1998;9(10): 1123-1126 (Pubitemid 28518152)
6. Lasso De La Vega MC, Zapater P, Such J, Sola-Vera J, et al. Toxic hepatitis associated with tamoxifen use. A case report and literature review. Gastroenterol Hepatol. 2002;25(4): 247-250 (Pubitemid 34847189)
7. Wogan GN. Review of the toxicology of tamoxifen. Semin Oncol. 1997;24(1, Suppl. 1): S1-87-S1-97 (Pubitemid 27104894)
8. Hard GC, Iatropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD(BR) rats. Cancer Res. 1993;53(19): 4534-4541 (Pubitemid 23304376)
9. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005;45: 177-202 (Pubitemid 40261802)
10. Ahotupa M, Hirsimäki P, Pärssinen R, Mäntylä E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis. 1994;15(5): 863-868 (Pubitemid 24156882)
11. Jatobá CA, de Rezende AA, de Paiva Rodrigues SJ, et al. Liver iron overload induced by tamoxifen in diabetic and non-diabetic female Wistar rats. Biometals. 2008;21(2): 171-178 (Pubitemid 351421985)
12. Bacon BR, Park CH, Brittenham GM, O'Neill R, Tavill AS. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology. 1985;5(5): 789-797 (Pubitemid 15236623)
13. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).Transfus Sci. 2000;23(3): 211-223
14. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004;11(16): 2161-2183 (Pubitemid 38967737)
15. Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin. 2006;30(2): 183-200
16. Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin. 2009;33(5): 386-397
17. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed).2009;1: 161-178
18. Barnabé N, Zastre JA, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicininduced myocyte cytotoxicity. Free Radic Biol Med. 2002;33(2): 266-275 (Pubitemid 34775198)
19. Eybl V, Kotyzová D, Kolek M, Koutensky J, Nielsen P. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicol Lett. 2002;128(1-3): 169-175 (Pubitemid 34183459)
20. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3(4): 294-300 (Pubitemid 39552423)
21. Tabassum H, Parvez S, Rehman H, Banerjee BD, Raisuddin S. Catechin as an antioxidant in liver mitochondrial toxicity: inhibition of tamoxifen-induced protein oxidation and lipid peroxidation. J Biochem Mol Toxicol. 2007;21(3): 110-117 (Pubitemid 47080837)
22. Parvez S, Tabassum H, Banerjee BD, Raisuddin S. Taurine prevents tamoxifen-induced mitochondrial oxidative damage in mice. Basic Clin Pharmacol Toxicol. 2008;102(4): 382-387 (Pubitemid 351393108)
23. El-Beshbishy HA. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective. J Biochem Mol Biol. 2005;38(3): 300-306 (Pubitemid 43034370)
24. Albukhari AA, GashlanHM, El-Beshbishy HA, Nagy AA, Abdel-Naim AB. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats. Food Chem Toxicol. 2009;47(7): 1689-1695